1. Home
  2. OIS vs CBIO Comparison

OIS vs CBIO Comparison

Compare OIS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OIS
  • CBIO
  • Stock Information
  • Founded
  • OIS 1995
  • CBIO 2003
  • Country
  • OIS United States
  • CBIO United States
  • Employees
  • OIS N/A
  • CBIO N/A
  • Industry
  • OIS Metal Fabrications
  • CBIO
  • Sector
  • OIS Industrials
  • CBIO
  • Exchange
  • OIS Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • OIS 285.8M
  • CBIO 308.0M
  • IPO Year
  • OIS 2001
  • CBIO N/A
  • Fundamental
  • Price
  • OIS $5.36
  • CBIO $16.99
  • Analyst Decision
  • OIS Buy
  • CBIO Strong Buy
  • Analyst Count
  • OIS 3
  • CBIO 2
  • Target Price
  • OIS $6.17
  • CBIO $25.00
  • AVG Volume (30 Days)
  • OIS 773.5K
  • CBIO 44.2K
  • Earning Date
  • OIS 07-28-2025
  • CBIO 08-23-2025
  • Dividend Yield
  • OIS N/A
  • CBIO N/A
  • EPS Growth
  • OIS N/A
  • CBIO N/A
  • EPS
  • OIS 0.08
  • CBIO N/A
  • Revenue
  • OIS $685,264,000.00
  • CBIO N/A
  • Revenue This Year
  • OIS $2.14
  • CBIO N/A
  • Revenue Next Year
  • OIS $6.71
  • CBIO N/A
  • P/E Ratio
  • OIS $64.71
  • CBIO N/A
  • Revenue Growth
  • OIS N/A
  • CBIO N/A
  • 52 Week Low
  • OIS $3.08
  • CBIO $11.06
  • 52 Week High
  • OIS $5.86
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • OIS 61.20
  • CBIO N/A
  • Support Level
  • OIS $5.13
  • CBIO N/A
  • Resistance Level
  • OIS $5.81
  • CBIO N/A
  • Average True Range (ATR)
  • OIS 0.23
  • CBIO 0.00
  • MACD
  • OIS 0.00
  • CBIO 0.00
  • Stochastic Oscillator
  • OIS 64.00
  • CBIO 0.00

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: